Dolutegravir Impact on Residual Replication

NCT02500446 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

HIV

Interventions

DRUG: dolutegravir
OTHER: Placebo

Sponsor

University of Melbourne

Collaborators

[object Object]
[object Object]